Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing Nilotinib versus Imatinib with switch to Nilotinib in absence of optimal response. SUSTRENIM Study – GIMEMA CML1415 - CML1415 - Sustrenim

Fondazione Gimema Franco Mandelli Onlus0 个研究点目标入组 450 人开始时间: 2024年6月4日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Patients eligible for inclusion in this study have to meet all of the following criteria: • Patients with a confirmed diagnosis of BCR/ABL+ CML in chronic phase o Documented chronic phase CML must meet all the following criteria: 1. < 15% blasts in peripheral blood 2. < 30% blasts plus promyelocytes in peripheral blood 3. < 20% basophils in the peripheral blood 4. = 100 x 109/L (= 100,000/mm3) platelets, Age =18, ECOG performance status of 0-2, Evidence of typical BCR-ABL transcripts which are amenable to standardized RQ-PCR, Adequate end organ function as defined by: o Total bilirubin < 1.5 x ULN (ULN = upper limit of normal in a local institution lab). Does not apply to patients with isolated hyperbilirubinemia (e.g., Gilbert’s disease) grade < 3 o SGOT (AST) and SGPT (ALT) = 3 x ULN o Serum amylase and lipase = 2 x ULN o Alkaline phosphatase = 2.5 x ULN o Serum creatinine < 1.5 x ULN, Written informed consent prior to any study procedures.

•Previous treatment with BCR-ABL inhibitors for more than 30 days., Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and for which cannot be either safely discontinued or switched to a different medication prior to starting study drug., Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment, Patients unable to understand and to comply with study instructions and requirements, Refusal to give informed consent., Expression of any atypical BCR-ABL transcripts, instead of the classical P210-encoding type with the e13a2 or the e14a2 junction at screening., Previous anticancer agents (hydroxyurea, anagrelide, interferon) for CML for more than three months., Poorly controlled diabetes mellitus (defined as HbA1c >8%, Prior documented history of coronary heart disease, including myocardial infarction, coronary bypass, coronary stent, and symptomatic angina as defined at page 30 in Exclusion Criteria., Uncontrolled hypertension, History of peripheral arterial occlusive disease., History of acute pancreatitis within 12 months of study entry, or a past medical history of chronic pancreatitis, Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers which cannot be either discontinued or switched to a different medication prior to starting study drug

发起方

Fondazione Gimema Franco Mandelli Onlus